Oryon Cell Therapies has emerged from stealth with a $21m Series A funding round to advance its autologous neuron replacement therapy for Parkinson’s disease. This funding brings Oryon’s total capital to $42m, enabling further development of its phase 1b/2a trial. The therapy involves unilateral implantation of fully developed A9 neurons, showing promising improvements in motor function and dopaminergic signaling. CEO Ron Cohen highlights the unique approach of treating one side of the brain, allowing for internal control comparisons. The company plans to explore bilateral treatment in future trials, addressing the strong placebo effect in Parkinson’s studies.
